US Patent Issued to INSERM (INSTITUT NATIONAL DE LA SANE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE BORDEAUX, CHU DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE on Nov. 11 for "Double deamidated form of Bcl-xL is a biomarker of platelet age" (French Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,467,924, issued on Nov. 11, was assigned to INSERM (INSTITUT NATIONAL DE LA SANE ET DE LA RECHERCHE MEDICALE (Paris), UNIVERSITE DE BORDEAUX (Bordeaux, France), CHU DE BORDEAUX (Bordeaux, France) and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris).

"Double deamidated form of Bcl-xL is a biomarker of platelet age" was invented by Chloe James (Pessac, France), Florian Beaumatin (Bordeaux, France) and Muriel Priault (Bordeaux, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "Deamidation is usually viewed as a post-translational modification that sets an expiration date on proteins. Among apoptosis regulators of the Bcl-2 family, Bcl-xL shows a un...